Article
Rho2-dependent cell wall remodeling boosts the fungistatic activity of manogepix against <i>Aspergillus fumigatus</i>
2025-10-20
Abstract excerpt
<h4>ABSTRACT</h4> Fosmanogepix is a new antifungal agent currently undergoing phase 3 clinical trials. Its active moiety, manogepix, inhibits Gwt1 which is an enzyme essential for the assembly and attachment of glycosylphosphatidylinositol anchors to cell wall proteins. Manogepix has a strong fungistatic activity against most human pathogenic fungal species. Here we characterized the activity of manogepix against...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 89e3fd87-8f5d-5af9-ba36-7e0257d75f1a
- DOI
- 10.1101/2025.10.20.683572
